Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma

Gao, Wei; Bing, Xue; Li, MingYan; Yang, Zhanhua; Li, Ying; Chen, Hua
June 2013
Medical Oncology;Jun2013, Vol. 30 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • Application of Biological Study for Met Expression to Cancer Therapy. Osada, Shinji; Yoshida, Kazuhiro // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 1, p58 

    Metastasization is an undesirable process in cancer development and may represent the most critical factor in deciding patient prognosis. Organ specificity of the metastasis process suggests the importance of the paracrine factors: one of the most potent paracrine regulators of tumor cell...

  • Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress. Gholamin, Sharareh; Fiuji, Hamid; Maftouh, Mina; Mirhafez, Reza; Shandiz, Fatemeh Homaei; Avan, Amir // Current Drug Targets;Dec2014, Vol. 15 Issue 14, p1302 

    Aberrant activation of receptor-tyrosine kinase c-Met/HGF pathway is shown to be associated with cell proliferation, invasion, metastasis and poor-prognosis in several tumor types, including upper gastrointestinal-malignancies. The interaction of c-Met with multiple signalling-pathways involved...

  • Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. Jinxuan Hou; Jixin Dong; Lijun Sun; Liying Geng; Jing Wang; Jialin Zheng; Yan Li; Bridge, Julia; Hinrichs, Steven H.; Shi-Jian Ding; Hou, Jinxuan; Dong, Jixin; Sun, Lijun; Geng, Liying; Wang, Jing; Zheng, Jialin; Li, Yan; Ding, Shi-Jian // Journal of Translational Medicine;2010 Supplement 1, Vol. 9 Issue Suppl 1, p64 

    Background: c-Met is a receptor tyrosine kinase (RTK) that is over-expressed in a variety of cancers and involved in cell growth, invasion, metastasis and angiogenesis. In this study, we investigated the role of c-Met in rhabdomyosarcoma (RMS) using its small molecule inhibitor...

  • The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. Steinway, Steven N.; Dang, Hien; You, Hanning; Rountree, C. Bart; Ding, Wei // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: c-Met, a high-affinity receptor for Hepatocyte Growth Factor (HGF), plays a critical role in tumor growth, invasion, and metastasis. Hepatocellular carcinoma (HCC) patients with activated HGF/c-Met signaling have a significantly worse prognosis. Targeted therapies using c-Met...

  • c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. Gayyed, Mariana Fathy; Abd El-Maqsoud, Nehad M. R.; El-Hameed El-Heeny, Amr Abd; Mohammed, Mostafa Fuad // Journal of Gastrointestinal Oncology;2015, Vol. 6 Issue 6, p618 

    Background: c-MET plays an important role in tumor proliferation, invasion and metastasis. In this study we examined the expression of c-MET in colorectal adenomas, primary adenocarcinomas and their corresponding lymph node, peritoneal and liver metastases. We correlated our...

  • Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Uddin, Shahab; Hussain, Azhar R.; Ahmed, Maqbool; Al-Dayel, Fouad; Bu, Rong; Bavi, Prashant; Al-Kuraya, Khawla S. // Laboratory Investigation (00236837);Sep2010, Vol. 90 Issue 9, p1346 

    Hepatocyte growth factor/c-MET has emerged as a potential therapeutic target for several cancers; however, its role in diffuse large B-cell lymphoma (DLBCL) has not been fully elucidated. In this study, we first investigated the role of c-Met in a large series of DLBCL tissues in a tissue...

  • Expression Patterns of PAX5, c-Met, and Paxillin in Neuroendocrine Tumors of the Lung. Jie Song; Mei Li; Tretiakova, Maria; Salgia, Ravi; Cagle, Philip T.; Husain, Aliya N. // Archives of Pathology & Laboratory Medicine;Nov2010, Vol. 134 Issue 11, p1702 

    Context.--c-Met is important in the pathogenesis, invasion, and spread of several forms of lung cancer, and multiple c-Met inhibitors are undergoing clinical trials. PAX5 has been shown to upregulate c-Met in small cell lung carcinoma (SCLC), and coinhibiting PAX5 and c-Met had a synergic effect...

  • Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Kitamura, S; Kondo, S; Shinomura, Y; Kanayama, S; Miyazaki, Y; Kiyohara, T; Hiraoka, S; Matsuzawa, Y // British Journal of Cancer;9/1/2000, Vol. 83 Issue 5, p668 

    The met proto-oncogene is the tyrosine kinase growth factor receptor for hepatocyte growth factor. In the present study, we investigated the role of met expression on the modulation of apoptosis in colorectal tumours. The gene expressions of c-met and the anti-apoptotic bcl-2 family, including...

  • HGF-independent potentiation of EGFR action by c-Met. Dulak, A M; Gubish, C T; Stabile, L P; Henry, C; Siegfried, J M // Oncogene;8/18/2011, Vol. 30 Issue 33, p3625 

    The c-Met receptor is a potential therapeutic target for non-small cell lung cancer (NSCLC). Signaling interactions between c-Met and the mutant epidermal growth factor receptor (EGFR) have been studied extensively, but signaling intermediates and biological consequences of lateral signaling to...

  • The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer. Hae-Yun Jung; Hyun-Jung Joo; Jong Kuk Park; Yeul Hong Kim // Cancer Research & Treatment;Dec2012, Vol. 44 Issue 4, p251 

    Purpose c-Met is an attractive potential target for novel therapeutic inhibition of human cancer, and c-Met tyrosine kinase inhibitors (TKIs) are effective growth inhibitors of various malignancies. However, their mechanisms in anticancer effects are not clear. In the present study, we...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics